This trial is testing a new MRI contrast agent for people with kidney problems and possible liver lesions. The goal is to see if the agent is safe and can help doctors better see the lesions.
1 Primary · 7 Secondary · Reporting Duration: 1 year
80 Total Participants · 1 Treatment Group
Primary Treatment: Mangoral · No Placebo Group · Phase 3
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: